The Experts below are selected from a list of 195 Experts worldwide ranked by ideXlab platform
Erik Munson - One of the best experts on this subject based on the ideXlab platform.
-
clinical laboratory assessment of mycoplasma genitalium transcription mediated Amplification using primary female urogenital specimens
Journal of Clinical Microbiology, 2016Co-Authors: Erik Munson, Maureen Napierala, Ronald F Schell, Holly Bykowski, Kimber L Munson, Pamela J Reiss, Jeanne E HryciukAbstract:Following analysis of primary cervix, vagina, and first-void female urine specimens for Chlamydia trachomatis , Neisseria gonorrhoeae , and Trichomonas vaginalis via commercial Transcription-Mediated Amplification (TMA), residual material was subjected to M. genitalium research-use-only TMA. Representation within a 2478-specimen retrospective study set was established by comparison to a six-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of C. trachomatis detection rate, specimen source distribution, clinic location, and age. M. genitalium was detected in 282 patients (11.4%). This rate was higher than T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%). Positive M. genitalium results were confirmed by repeat testing or alternative target TMA at a rate of 98.7%. Mean age of M. genitalium -infected females (24.7) was less than T. vaginalis (mean 30.1; P C. trachomatis (mean 23.8; P = 0.003). Of 566 patient encounters positive for at least one sexually-transmitted infection (STI), 35.9% exhibited sole detection of M. genitalium ( P ≤ 0.0004 versus sole detection of other STI agents) and 26.1% were solely positive for T. vaginalis ( P C. trachomatis ). M. genitalium and T. vaginalis detection rates among 755 patients at urban emergency departments were 14.6% and 13.0%, respectively ( P = 0.37). A 10.0% M. genitalium detection rate from other facilities exceeded that of T. vaginalis (7.2%; P = 0.004). Incorporation of M. genitalium TMA into comprehensive testing programs will detect M. genitalium in a significant proportion of females, particularly those in outpatient OB/GYN settings.
-
insights into trichomoniasis as a result of highly sensitive molecular diagnostics screening in a high prevalence sexually transmitted infection community
Expert Review of Anti-infective Therapy, 2013Co-Authors: Erik Munson, Maureen Napierala, Ronald F SchellAbstract:We briefly examine the clinical significance and pathogenesis of Trichomonas vaginalis and provide a comprehensive summary of non-molecular and molecular diagnostics for the organism. Transcription-Mediated Amplification (TMA) identifies more cases of trichomoniasis than other detection modalities. In our high-prevalence sexually transmitted infection community, TMA has allowed us to investigate female and male trichomoniasis epidemiology. Distribution of the organism is community-wide and similar between Caucasian-majority geographical areas and African–American-majority locales. First-void urine provides an excellent means for laboratory diagnosis of T. vaginalis in both genders. While trichomoniasis affects older age demographics, urine screening in younger females demonstrates elevated T. vaginalis prevalence. These data promote widespread adoption of TMA for diagnosis of T. vaginalis and further epidemiological assessments. Since trichomoniasis is the most-prevalent non-viral etiology of sexually tra...
-
three year history of transcription mediated Amplification based trichomonas vaginalis analyte specific reagent testing in a subacute care patient population
Journal of Clinical Microbiology, 2011Co-Authors: Maureen Napierala, Erik Munson, Kimber L Munson, Cheryl Miller, Jason Burtch, Timothy Kramme, Robin Olson, Jeanne E HryciukAbstract:ABSTRACT A total of 7,899 specimens submitted for live clinical Trichomonas vaginalis analyte-specific reagent (ASR) screening from 2008 to 2010 were audited on the basis of patient gender, specimen source, molecular Neisseria gonorrhoeae and Chlamydia trachomatis results, and relative light unit (RLU) data yielded by T. vaginalis ASR. Only 1.4% of the screening was ordered by emergency department clinicians. The screening volume in 2010 was 126% higher than that in 2008. The proportions of annual female and male screening remained consistent throughout the 3-year interval (∼92 and 8%, respectively). Although 71.8 and 9.5% of screening was performed on endocervical and vaginal specimens, respectively, over the 3-year period, no significant difference was noted in the T. vaginalis detection rates (8.9 and 8.6%, P = 0.85). Increased T. vaginalis detection was derived from female urine specimens (12.6%) compared to female genital swabs ( P = 0.0004). The proportion of female urine screening increased during the 3-year interval ( P P = 0.53). The mean RLU value for 714 positive specimens was 3,971,441; analogous values for each female specimen source and combined male source testing showed no variance ( P ≥ 0.29). Combined-gender T. vaginalis detection rate (9.1%) was significantly greater than those of C. trachomatis (5.9%) and N. gonorrhoeae (1.5%; P
-
trichomonas vaginalis transcription mediated Amplification based analyte specific reagent and alternative target testing of primary clinical vaginal saline suspensions
Diagnostic Microbiology and Infectious Disease, 2010Co-Authors: Erik Munson, Maureen Napierala, Jeanne E Hryciuk, Janice Basile, Cheryl Miller, Jason Burtch, Ronald F SchellAbstract:Following wet mount analysis, 255 vaginal saline suspensions were aliquoted to lysis medium for Transcription-Mediated Amplification (TMA)-based Trichomonas vaginalis analyte-specific reagent testing (ASR) (Gen-Probe, San Diego, CA). Specimens with visible T. vaginalis were then refrigerated, with additional aliquoting at later intervals. Twenty-four wet mount-positive specimens (9.4%) yielded a median luminescent value (×1000, relative light unit [RLU]) of 4736. In contrast, RLU ranged from 1 to 21 following ASR of 204 wet mount-negative specimens. Twenty-seven wet mount-negative specimens (10.5%) were positive by ASR and subsequently positive via T. vaginalis alternative target TMA (Gen-Probe). Discrepancies were additionally resolved by demonstration of T. vaginalis nucleic acid from a separate endocervical collection. T. vaginalis nucleic acid was detectable following prolonged storage, following minimal incubation in lysis medium, and from low-volume aliquots of sparsely populated specimens. T. vaginalis ASR adequately detects T. vaginalis from vaginal saline suspension aliquots, providing a simple specimen alternative for a highly sensitive laboratory diagnosis of trichomoniasis.
Ronald F Schell - One of the best experts on this subject based on the ideXlab platform.
-
clinical laboratory assessment of mycoplasma genitalium transcription mediated Amplification using primary female urogenital specimens
Journal of Clinical Microbiology, 2016Co-Authors: Erik Munson, Maureen Napierala, Ronald F Schell, Holly Bykowski, Kimber L Munson, Pamela J Reiss, Jeanne E HryciukAbstract:Following analysis of primary cervix, vagina, and first-void female urine specimens for Chlamydia trachomatis , Neisseria gonorrhoeae , and Trichomonas vaginalis via commercial Transcription-Mediated Amplification (TMA), residual material was subjected to M. genitalium research-use-only TMA. Representation within a 2478-specimen retrospective study set was established by comparison to a six-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of C. trachomatis detection rate, specimen source distribution, clinic location, and age. M. genitalium was detected in 282 patients (11.4%). This rate was higher than T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%). Positive M. genitalium results were confirmed by repeat testing or alternative target TMA at a rate of 98.7%. Mean age of M. genitalium -infected females (24.7) was less than T. vaginalis (mean 30.1; P C. trachomatis (mean 23.8; P = 0.003). Of 566 patient encounters positive for at least one sexually-transmitted infection (STI), 35.9% exhibited sole detection of M. genitalium ( P ≤ 0.0004 versus sole detection of other STI agents) and 26.1% were solely positive for T. vaginalis ( P C. trachomatis ). M. genitalium and T. vaginalis detection rates among 755 patients at urban emergency departments were 14.6% and 13.0%, respectively ( P = 0.37). A 10.0% M. genitalium detection rate from other facilities exceeded that of T. vaginalis (7.2%; P = 0.004). Incorporation of M. genitalium TMA into comprehensive testing programs will detect M. genitalium in a significant proportion of females, particularly those in outpatient OB/GYN settings.
-
insights into trichomoniasis as a result of highly sensitive molecular diagnostics screening in a high prevalence sexually transmitted infection community
Expert Review of Anti-infective Therapy, 2013Co-Authors: Erik Munson, Maureen Napierala, Ronald F SchellAbstract:We briefly examine the clinical significance and pathogenesis of Trichomonas vaginalis and provide a comprehensive summary of non-molecular and molecular diagnostics for the organism. Transcription-Mediated Amplification (TMA) identifies more cases of trichomoniasis than other detection modalities. In our high-prevalence sexually transmitted infection community, TMA has allowed us to investigate female and male trichomoniasis epidemiology. Distribution of the organism is community-wide and similar between Caucasian-majority geographical areas and African–American-majority locales. First-void urine provides an excellent means for laboratory diagnosis of T. vaginalis in both genders. While trichomoniasis affects older age demographics, urine screening in younger females demonstrates elevated T. vaginalis prevalence. These data promote widespread adoption of TMA for diagnosis of T. vaginalis and further epidemiological assessments. Since trichomoniasis is the most-prevalent non-viral etiology of sexually tra...
-
trichomonas vaginalis transcription mediated Amplification based analyte specific reagent and alternative target testing of primary clinical vaginal saline suspensions
Diagnostic Microbiology and Infectious Disease, 2010Co-Authors: Erik Munson, Maureen Napierala, Jeanne E Hryciuk, Janice Basile, Cheryl Miller, Jason Burtch, Ronald F SchellAbstract:Following wet mount analysis, 255 vaginal saline suspensions were aliquoted to lysis medium for Transcription-Mediated Amplification (TMA)-based Trichomonas vaginalis analyte-specific reagent testing (ASR) (Gen-Probe, San Diego, CA). Specimens with visible T. vaginalis were then refrigerated, with additional aliquoting at later intervals. Twenty-four wet mount-positive specimens (9.4%) yielded a median luminescent value (×1000, relative light unit [RLU]) of 4736. In contrast, RLU ranged from 1 to 21 following ASR of 204 wet mount-negative specimens. Twenty-seven wet mount-negative specimens (10.5%) were positive by ASR and subsequently positive via T. vaginalis alternative target TMA (Gen-Probe). Discrepancies were additionally resolved by demonstration of T. vaginalis nucleic acid from a separate endocervical collection. T. vaginalis nucleic acid was detectable following prolonged storage, following minimal incubation in lysis medium, and from low-volume aliquots of sparsely populated specimens. T. vaginalis ASR adequately detects T. vaginalis from vaginal saline suspension aliquots, providing a simple specimen alternative for a highly sensitive laboratory diagnosis of trichomoniasis.
Charlotte A Gaydos - One of the best experts on this subject based on the ideXlab platform.
-
clinical validation of the aptima bacterial vaginosis and aptima candida trichomonas vaginitis assays results from a prospective multicenter clinical study
Journal of Clinical Microbiology, 2019Co-Authors: Jane R Schwebke, Charlotte A Gaydos, Stephanie N Taylor, Ronald Ackerman, Robert Schlaberg, Neil B Quigley, Steven E Chavoustie, Paul Nyirjesy, Carmelle V Remillard, Philip EstesAbstract:Infectious vaginitis due to bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginalis accounts for a significant proportion of all gynecologic visits in the United States. A prospective multicenter clinical study was conducted to validate the performance of two new in vitro diagnostic Transcription-Mediated Amplification nucleic acid Amplification tests (NAATs) for diagnosis of BV, VVC, and trichomoniasis. Patient- and clinician-collected vaginal-swab samples obtained from women with symptoms of vaginitis were tested with the Aptima BV and Aptima Candida/Trichomonas vaginitis (CV/TV) assays. The results were compared to Nugent (plus Amsel for intermediate Nugent) scores for BV, Candida cultures and DNA sequencing for VVC, and a composite of NAAT and culture for T. vaginalis The prevalences of infection were similar for clinician- and patient-collected samples: 49% for BV, 29% for VVC due to the Candida species group, 4% for VVC due to Candida glabrata, and 10% for T. vaginalis Sensitivity and specificity estimates for the investigational tests in clinician-collected samples were 95.0% and 89.6%, respectively, for BV; 91.7% and 94.9% for the Candida species group; 84.7% and 99.1% for C. glabrata; and 96.5% and 95.1% for T. vaginalis Sensitivities and specificities were similar in patient-collected samples. In a secondary analysis, clinicians' diagnoses, in-clinic assessments, and investigational-assay results were compared to gold standard reference methods. Overall, the investigational assays had higher sensitivity and specificity than clinicians' diagnoses and in-clinic assessments, indicating that the investigational assays were more predictive of infection than traditional diagnostic methods. These results provide clinical-efficacy evidence for two in vitro diagnostic NAATs that can detect the main causes of vaginitis.
-
mycoplasma genitalium accurate diagnosis is necessary for adequate treatment
The Journal of Infectious Diseases, 2017Co-Authors: Charlotte A GaydosAbstract:Background Mycoplasma genitalium is very difficult to grow in culture but has been more able to be studied for disease associations since the advent of research molecular Amplification assays. Polymerase chain reaction (PCR) and other molecular assays have demonstrated an association with adverse disease outcomes, such as urethritis or nongonococcal urethritis in men and adverse reproductive sequelae in women-for example, cervicitis, endometritis, and pelvic inflammatory disease (PID), including an association with risk for human immunodeficiency virus. The lack of commercially available diagnostic assays has limited widespread routine testing. Increasing reports of high rates of resistance to azithromycin detected in research studies have heightened the need available commercial diagnostic assays as well as standardized methods for detecting resistance markers. This review covers available molecular methods for the diagnosis of M. genitalium and assays to predict the antibiotic susceptibility to azithromycin. Methods A PubMed (US National Library of Medicine and National Institutes of Health) search was conducted for literature published between 2000 and 2016, using the search terms Mycoplasma genitalium, M. genitalium, diagnosis, and detection. Results Early PCR diagnostic tests focused on the MPa adhesion gene and the 16S ribosomal RNA gene. Subsequently, a Transcription-Mediated Amplification assay targeting ribosomes was developed and widely used to study the epidemiology of M. genitalium. Newer methods have proliferated and include quantitative PCR for organism load, AmpliSens PCR, PCR for the pdhD gene, a PCR-based microarray for multiple sexually transmitted infections, and multiplex PCRs. None yet are cleared by the Food and Drug Administration in the United States, although several assays are CE marked in Europe. As well, many research assays, including PCR, gene sequencing, and melt curve analysis, have been developed to detect the 23S ribosomal RNA gene mutations that confer resistance to azithromycin. One recently developed assay can test for both M. genitalium and azithromycin resistance mutations at the same time. Conclusions It is recommended that more commercial assays to both diagnose this organism and guide treatment choices should be developed and made available through regulatory approval. Research is needed to establish the cost-effectiveness of routine M. genitalium testing in symptomatic patients and screening in all individuals at high risk of acquiring and transmitting sexually transmitted infections.
-
a service evaluation of the gen probe aptima nucleic acid Amplification test for trichomonas vaginalis should it change whom we screen for infection
Sexually Transmitted Infections, 2015Co-Authors: Emma Hathorn, Charlotte A Gaydos, Matthew Page, James Hodson, J D C RossAbstract:Objective A service evaluation of the new Gen-Probe APTIMA nucleic acid Amplification test was performed to determine the prevalence of Trichomonas vaginalis (TV) infection in a UK sexual health clinic and identify risk factors to inform an appropriate TV screening strategy. Method Unselected patients presenting with a new clinical episode were offered TV testing with Gen Probe Transcription-Mediated Amplification (TV TMA) in addition to routine sexually transmitted infection screening. Asymptomatic females provided a self-collected vulvovaginal specimen and asymptomatic men a first-void urine sample. Symptomatic patients were examined and a urethral swab taken from men and two posterior vaginal swabs from females; one for culture and one for TV TMA testing. Demographic and clinical data were collected on all patients positive for TV infection and 100 randomly selected TV-negative controls. Results 3503 patients underwent TV TMA testing during the evaluation period. The prevalence of TV infection was 21/1483, 1.4% (95% CI 0.9% to 2.2%) in men and 72/2020, 3.6% (95% CI 2.8% to 4.5%) in women. The rate of TV positivity was higher in Black Caribbean patients compared with Caucasian patients (men 5.4% vs 0.1%, p Conclusions While screening all patients with TV TMA will identify more TV infections, the UK prevalence remains low and this approach is unlikely to be cost effective. In addition to testing symptomatic patients, targeted testing of high-risk asymptomatic groups using TV TMA should be considered.
-
adolescent women can perform a point of care test for trichomoniasis as accurately as clinicians
Sexually Transmitted Infections, 2010Co-Authors: Jill S Huppert, Elizabeth A Hesse, Grace Kim, Michael Kim, Patricia Agreda, Nicole Quinn, Charlotte A GaydosAbstract:Objectives To compare the accuracy (ie, correlation, sensitivity, specificity) of self-performed point-of-care (POC) tests with clinician-performed tests for trichomoniasis in adolescent women. Methods Sexually experienced women aged 14–22 years (n=209) collected a vaginal swab and performed a POC test for trichomoniasis. Using a speculum, the clinician obtained vaginal swabs that were tested for trichomoniasis using the POC test, wet mount, culture and Transcription-Mediated Amplification (TMA) using standard and alternative primers. Self and clinician results were compared with true positives, defined as either culture-positive or TMA-positive with both sets of primers. Results Participants9 mean age was 17.8 years; 87% were African-American; 74% reported vaginal itching or discharge and 51 (24%) had trichomoniasis. Over 99% correctly performed and interpreted her self-test. Self and clinician POC tests were highly correlated (95.7% agreement, κ 0.87). Compared with true positives, the sensitivity of the self-POC test was 78% (CI 65% to 89%), similar to that of the clinician-POC test (84%, CI 71% to 93%) and culture (82%, CI 69% to 92%), and significantly better than wet mount (39%, CI 26% to 54%). The specificity of the self-POC test was 99% (CI 96% to 100%), similar to that of the clinician-POC test (100%, CI 98% to 100%). The sensitivity of the self-POC test was not affected by vaginal symptoms or other variables. Conclusions Young women performing a self-POC test detected as many trichomoniasis infections as clinician-POC tests or culture, twice as many as wet mount and slightly fewer than an amplified test. Incorporating self-obtained or self-performed POC tests into routine practice could effectively increase the identification and treatment of trichomoniasis in this vulnerable population.
-
comparison between the gen probe transcription mediated Amplification trichomonas vaginalis research assay and real time pcr for trichomonas vaginalis detection using a roche lightcycler instrument with female self obtained vaginal swab samples and m
Journal of Clinical Microbiology, 2006Co-Authors: Andrew Hardick, Justin Hardick, Billie Jo Wood, Charlotte A GaydosAbstract:This study compared two assays for Trichomonas vaginalis detection, Gen-Probe's Transcription-Mediated Amplification (TMA) assay for Trichomonas vaginalis and BTUB FRET PCR, using self-obtained clinical samples from 611 patients. Infection status was defined as two positive results by two different tests. The initial TMA assay sensitivity was 96.7%; specificity was 97.5%. The TMA assay was comparable to BTUB FRET PCR.
Maureen Napierala - One of the best experts on this subject based on the ideXlab platform.
-
clinical laboratory assessment of mycoplasma genitalium transcription mediated Amplification using primary female urogenital specimens
Journal of Clinical Microbiology, 2016Co-Authors: Erik Munson, Maureen Napierala, Ronald F Schell, Holly Bykowski, Kimber L Munson, Pamela J Reiss, Jeanne E HryciukAbstract:Following analysis of primary cervix, vagina, and first-void female urine specimens for Chlamydia trachomatis , Neisseria gonorrhoeae , and Trichomonas vaginalis via commercial Transcription-Mediated Amplification (TMA), residual material was subjected to M. genitalium research-use-only TMA. Representation within a 2478-specimen retrospective study set was established by comparison to a six-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of C. trachomatis detection rate, specimen source distribution, clinic location, and age. M. genitalium was detected in 282 patients (11.4%). This rate was higher than T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%). Positive M. genitalium results were confirmed by repeat testing or alternative target TMA at a rate of 98.7%. Mean age of M. genitalium -infected females (24.7) was less than T. vaginalis (mean 30.1; P C. trachomatis (mean 23.8; P = 0.003). Of 566 patient encounters positive for at least one sexually-transmitted infection (STI), 35.9% exhibited sole detection of M. genitalium ( P ≤ 0.0004 versus sole detection of other STI agents) and 26.1% were solely positive for T. vaginalis ( P C. trachomatis ). M. genitalium and T. vaginalis detection rates among 755 patients at urban emergency departments were 14.6% and 13.0%, respectively ( P = 0.37). A 10.0% M. genitalium detection rate from other facilities exceeded that of T. vaginalis (7.2%; P = 0.004). Incorporation of M. genitalium TMA into comprehensive testing programs will detect M. genitalium in a significant proportion of females, particularly those in outpatient OB/GYN settings.
-
insights into trichomoniasis as a result of highly sensitive molecular diagnostics screening in a high prevalence sexually transmitted infection community
Expert Review of Anti-infective Therapy, 2013Co-Authors: Erik Munson, Maureen Napierala, Ronald F SchellAbstract:We briefly examine the clinical significance and pathogenesis of Trichomonas vaginalis and provide a comprehensive summary of non-molecular and molecular diagnostics for the organism. Transcription-Mediated Amplification (TMA) identifies more cases of trichomoniasis than other detection modalities. In our high-prevalence sexually transmitted infection community, TMA has allowed us to investigate female and male trichomoniasis epidemiology. Distribution of the organism is community-wide and similar between Caucasian-majority geographical areas and African–American-majority locales. First-void urine provides an excellent means for laboratory diagnosis of T. vaginalis in both genders. While trichomoniasis affects older age demographics, urine screening in younger females demonstrates elevated T. vaginalis prevalence. These data promote widespread adoption of TMA for diagnosis of T. vaginalis and further epidemiological assessments. Since trichomoniasis is the most-prevalent non-viral etiology of sexually tra...
-
three year history of transcription mediated Amplification based trichomonas vaginalis analyte specific reagent testing in a subacute care patient population
Journal of Clinical Microbiology, 2011Co-Authors: Maureen Napierala, Erik Munson, Kimber L Munson, Cheryl Miller, Jason Burtch, Timothy Kramme, Robin Olson, Jeanne E HryciukAbstract:ABSTRACT A total of 7,899 specimens submitted for live clinical Trichomonas vaginalis analyte-specific reagent (ASR) screening from 2008 to 2010 were audited on the basis of patient gender, specimen source, molecular Neisseria gonorrhoeae and Chlamydia trachomatis results, and relative light unit (RLU) data yielded by T. vaginalis ASR. Only 1.4% of the screening was ordered by emergency department clinicians. The screening volume in 2010 was 126% higher than that in 2008. The proportions of annual female and male screening remained consistent throughout the 3-year interval (∼92 and 8%, respectively). Although 71.8 and 9.5% of screening was performed on endocervical and vaginal specimens, respectively, over the 3-year period, no significant difference was noted in the T. vaginalis detection rates (8.9 and 8.6%, P = 0.85). Increased T. vaginalis detection was derived from female urine specimens (12.6%) compared to female genital swabs ( P = 0.0004). The proportion of female urine screening increased during the 3-year interval ( P P = 0.53). The mean RLU value for 714 positive specimens was 3,971,441; analogous values for each female specimen source and combined male source testing showed no variance ( P ≥ 0.29). Combined-gender T. vaginalis detection rate (9.1%) was significantly greater than those of C. trachomatis (5.9%) and N. gonorrhoeae (1.5%; P
-
trichomonas vaginalis transcription mediated Amplification based analyte specific reagent and alternative target testing of primary clinical vaginal saline suspensions
Diagnostic Microbiology and Infectious Disease, 2010Co-Authors: Erik Munson, Maureen Napierala, Jeanne E Hryciuk, Janice Basile, Cheryl Miller, Jason Burtch, Ronald F SchellAbstract:Following wet mount analysis, 255 vaginal saline suspensions were aliquoted to lysis medium for Transcription-Mediated Amplification (TMA)-based Trichomonas vaginalis analyte-specific reagent testing (ASR) (Gen-Probe, San Diego, CA). Specimens with visible T. vaginalis were then refrigerated, with additional aliquoting at later intervals. Twenty-four wet mount-positive specimens (9.4%) yielded a median luminescent value (×1000, relative light unit [RLU]) of 4736. In contrast, RLU ranged from 1 to 21 following ASR of 204 wet mount-negative specimens. Twenty-seven wet mount-negative specimens (10.5%) were positive by ASR and subsequently positive via T. vaginalis alternative target TMA (Gen-Probe). Discrepancies were additionally resolved by demonstration of T. vaginalis nucleic acid from a separate endocervical collection. T. vaginalis nucleic acid was detectable following prolonged storage, following minimal incubation in lysis medium, and from low-volume aliquots of sparsely populated specimens. T. vaginalis ASR adequately detects T. vaginalis from vaginal saline suspension aliquots, providing a simple specimen alternative for a highly sensitive laboratory diagnosis of trichomoniasis.
Jeanne E Hryciuk - One of the best experts on this subject based on the ideXlab platform.
-
clinical laboratory assessment of mycoplasma genitalium transcription mediated Amplification using primary female urogenital specimens
Journal of Clinical Microbiology, 2016Co-Authors: Erik Munson, Maureen Napierala, Ronald F Schell, Holly Bykowski, Kimber L Munson, Pamela J Reiss, Jeanne E HryciukAbstract:Following analysis of primary cervix, vagina, and first-void female urine specimens for Chlamydia trachomatis , Neisseria gonorrhoeae , and Trichomonas vaginalis via commercial Transcription-Mediated Amplification (TMA), residual material was subjected to M. genitalium research-use-only TMA. Representation within a 2478-specimen retrospective study set was established by comparison to a six-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of C. trachomatis detection rate, specimen source distribution, clinic location, and age. M. genitalium was detected in 282 patients (11.4%). This rate was higher than T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%). Positive M. genitalium results were confirmed by repeat testing or alternative target TMA at a rate of 98.7%. Mean age of M. genitalium -infected females (24.7) was less than T. vaginalis (mean 30.1; P C. trachomatis (mean 23.8; P = 0.003). Of 566 patient encounters positive for at least one sexually-transmitted infection (STI), 35.9% exhibited sole detection of M. genitalium ( P ≤ 0.0004 versus sole detection of other STI agents) and 26.1% were solely positive for T. vaginalis ( P C. trachomatis ). M. genitalium and T. vaginalis detection rates among 755 patients at urban emergency departments were 14.6% and 13.0%, respectively ( P = 0.37). A 10.0% M. genitalium detection rate from other facilities exceeded that of T. vaginalis (7.2%; P = 0.004). Incorporation of M. genitalium TMA into comprehensive testing programs will detect M. genitalium in a significant proportion of females, particularly those in outpatient OB/GYN settings.
-
three year history of transcription mediated Amplification based trichomonas vaginalis analyte specific reagent testing in a subacute care patient population
Journal of Clinical Microbiology, 2011Co-Authors: Maureen Napierala, Erik Munson, Kimber L Munson, Cheryl Miller, Jason Burtch, Timothy Kramme, Robin Olson, Jeanne E HryciukAbstract:ABSTRACT A total of 7,899 specimens submitted for live clinical Trichomonas vaginalis analyte-specific reagent (ASR) screening from 2008 to 2010 were audited on the basis of patient gender, specimen source, molecular Neisseria gonorrhoeae and Chlamydia trachomatis results, and relative light unit (RLU) data yielded by T. vaginalis ASR. Only 1.4% of the screening was ordered by emergency department clinicians. The screening volume in 2010 was 126% higher than that in 2008. The proportions of annual female and male screening remained consistent throughout the 3-year interval (∼92 and 8%, respectively). Although 71.8 and 9.5% of screening was performed on endocervical and vaginal specimens, respectively, over the 3-year period, no significant difference was noted in the T. vaginalis detection rates (8.9 and 8.6%, P = 0.85). Increased T. vaginalis detection was derived from female urine specimens (12.6%) compared to female genital swabs ( P = 0.0004). The proportion of female urine screening increased during the 3-year interval ( P P = 0.53). The mean RLU value for 714 positive specimens was 3,971,441; analogous values for each female specimen source and combined male source testing showed no variance ( P ≥ 0.29). Combined-gender T. vaginalis detection rate (9.1%) was significantly greater than those of C. trachomatis (5.9%) and N. gonorrhoeae (1.5%; P
-
trichomonas vaginalis transcription mediated Amplification based analyte specific reagent and alternative target testing of primary clinical vaginal saline suspensions
Diagnostic Microbiology and Infectious Disease, 2010Co-Authors: Erik Munson, Maureen Napierala, Jeanne E Hryciuk, Janice Basile, Cheryl Miller, Jason Burtch, Ronald F SchellAbstract:Following wet mount analysis, 255 vaginal saline suspensions were aliquoted to lysis medium for Transcription-Mediated Amplification (TMA)-based Trichomonas vaginalis analyte-specific reagent testing (ASR) (Gen-Probe, San Diego, CA). Specimens with visible T. vaginalis were then refrigerated, with additional aliquoting at later intervals. Twenty-four wet mount-positive specimens (9.4%) yielded a median luminescent value (×1000, relative light unit [RLU]) of 4736. In contrast, RLU ranged from 1 to 21 following ASR of 204 wet mount-negative specimens. Twenty-seven wet mount-negative specimens (10.5%) were positive by ASR and subsequently positive via T. vaginalis alternative target TMA (Gen-Probe). Discrepancies were additionally resolved by demonstration of T. vaginalis nucleic acid from a separate endocervical collection. T. vaginalis nucleic acid was detectable following prolonged storage, following minimal incubation in lysis medium, and from low-volume aliquots of sparsely populated specimens. T. vaginalis ASR adequately detects T. vaginalis from vaginal saline suspension aliquots, providing a simple specimen alternative for a highly sensitive laboratory diagnosis of trichomoniasis.